secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001558370-24-015526
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma Q3 net loss $5.5M; Phase 2 Tail wind enrolled, topline data expected by year-end
--------------------------------------------------------------------------------

- Net loss $5.5M ($0.15/share) vs $31.2M loss in Q3 2023; includes $6.9M non-cash gain on convertible debt.
- Grant revenue $3.0M (DoD/MTEC) vs $1.2M; R&D expense $9.5M; cash $17.1M as of Sep 30, 2024.
- Phase 2 Tail wind (inhaled AP-PA02 for NCFB) enrollment complete; topline data expected by year-end 2024.
- Phase 1b/2a diSArm (IV AP-SA02 for S. aureus bacteremia) enrollment complete; topline data Q1 2025.
- Extended convertible debt and credit agreement maturity to Jan 10, 2026; appointed David House SVP Finance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000155837024015526/0001558370-24-015526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000155837024015526/armp-20241113x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer